Dry AMD, often seen in population over the age of 60, accounts for 85% of all AMD cases. The pathogenesis of early AMD is characterized by lipid and protein accumulation in the sub-RPE regions as “drusen”. These lipid deposits are thought to primarily interfere with the fluid efflux from the RPE across Bruch’s membrane (the innermost layer of the choroid), thereby inflicting stress (insufficient supply of oxygen and nutritions) on the RPE. Dry AMD, although a slow developing disease, can still lead to permanent vision loss。According to the WHO, there are 170 millions of dry AMD patients worldwide in 2022, and will be approaching 204 millions in 2030.

No standard treatment up to date for dry AMD because of the causes of the disease are multifactorial and complex. Human studies adopting a variety of therapeutic approaches for the disease and its related conditions are widely documented, but no promising result yet.

TO-O-1006 eye drops is in early stage of pre-clinical study.

Ref:
World report on vision. Geneva: WHO; 2019.